Tag Archives: inequitable conduct

G S Cleantech Petitions Fed. Cir. for Rehearing En Banc

Posted on May 21, 2020 by Warren Woessner

Before you read this post, please read or re-read my post of March 9, 2020, that summarized the panel decision in some detail. The case involves the district court’s finding of inequitable conduct by both CleanTech and their attorneys via … Continue reading →

Posted in 102 Patentability, Federal Circuit, Inequitable Conduct/Rule 56, s.102 | Tagged , , | Leave a comment

IPO Chat Channel: Inequitable Conduct – A Refresher & Update – April 23rd

Posted on April 21, 2020 by Warren Woessner

Have findings of inequitable conduct due to egregious misconduct become more common post-Therasense or can a simple failure to disclose material prior art still lead to a finding of inequitable conduct? What are the possible consequences to both litigators and … Continue reading →

Posted in Inequitable Conduct/Rule 56, Prior Art, Uncategorized | Tagged , , | Leave a comment

American Calcar v. Amer. Honda Motor Co. – Therasense Goes Out For a Test Drive

Posted on September 30, 2014 by Warren Woessner

On Friday, in American Calcar v. Amer. Honda Motor Co., App. No. 2013-1061 (Fed. Cir., September 26, 2014) a divided Fed. Cir. panel affirmed the district court’s ruling, following remand, that three patents on a multimedia system for vehicle information … Continue reading →

Posted in Inequitable Conduct/Rule 56 | Tagged , , , , , , , | 1 Comment

In re Rosuvastatin Calcium Patent Litigation – Making “Therasense” out of Confusion

Posted on December 20, 2012 by Warren Woessner

Recently, a divided three judge panel sorting out a multi-party Hatch-Waxman suit, ruled that the patentee, Shinonogi, had not committed inequitable conduct in obtaining the patent that was subsequently reissued so as to obtain narrow claims focused on Rosuvastatin, or … Continue reading →

Posted in Inequitable Conduct/Rule 56, Reissue | Tagged , , , , , , , , , , , , , , , , | 1 Comment